10-(3-Dimethylamino-propyl)-3-methylmercapto-phenothiazin | 1039-59-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻嗪类
• 英文名称: 10-(3-Dimethylamino-propyl)-3-methylmercapto-phenothiazin
• 英文别名: N-<3-Dimethylamino-propyl>-2-methylmercapto-phenothiazin；dimethyl-[3-(2-methylsulfanyl-phenothiazin-10-yl)-propyl]-amine；thiomethylpromazine；N,N-dimethyl-3-(2-methylsulfanylphenothiazin-10-yl)propan-1-amine
• CAS: 1039-59-4
• 化学式: C₁₈H₂₂N₂S₂
• 分子量: 330.518
• InChiKey: VAKQWULGGDTKGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  22
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  57.1
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-甲巯基吩噻嗪 在 sodium hydride 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 乙腈 、 mineral oil 为溶剂， 生成 10-(3-Dimethylamino-propyl)-3-methylmercapto-phenothiazin
  参考文献：
  名称：

  吩噻嗪类化合物及其制备方法和应用

  摘要：

  本发明涉及一种具有抗癌作用的吩噻嗪类化合物和该化合物的制备方法，此外，本发明还涉及该类化合物在制备抗癌药物中的应用，以及该类化合物作为有效成分的抗癌药物。本发明通过对吩噻嗪三元连环母核进行修饰得到具有广谱抗癌作用的化合物，合成方法简单、产率高；该类吩噻嗪化合物对于人乳腺癌细胞株MCF‑7和人肝癌细胞株Hep‑G2均有一定的抑制作用，为满足临床需求的新药提供新思路。

  公开号：

  CN104829554B

文献信息

• COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES
  申请人：Johansen Lisa M.

  公开号：US20100009970A1

  公开（公告）日：2010-01-14

  The present invention features compositions, methods, and kits useful in the treatment of viral diseases. In certain embodiments, the viral disease is caused by a single stranded RNA virus, a flaviviridae virus, or a hepatic virus. In particular embodiments, the viral disease is viral hepatitis (e.g., hepatitis A, hepatitis B, hepatitis C, hepatitis D, hepatitis E) and the agent or combination of agents includes sertraline, a sertraline analog, UK-416244, or a UK-416244 analog. Also featured are screening methods for identification of novel compounds that may be used to treat a viral disease.

  本发明涉及用于治疗病毒性疾病的组合物、方法和试剂盒。在某些实施方式中，病毒性疾病是由单链RNA病毒、黄病毒科病毒或肝病毒引起的。在特定实施方式中，病毒性疾病是病毒性肝炎（例如甲型肝炎、乙型肝炎、丙型肝炎、丁型肝炎、戊型肝炎），药剂或药剂组合包括舍曲林、舍曲林类似物、UK-416244或UK-416244类似物。还包括用于鉴定可用于治疗病毒性疾病的新化合物的筛选方法。
• Use of combinations comprising a corticosteroid and a pyrimidopyrimidine in the treatment of inflammatory diseases
  申请人：Combinatorx, Incorporated

  公开号：EP2070550A1

  公开（公告）日：2009-06-17

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

  本发明的特点是通过向患者单独或与一种或多种附加制剂联合使用四取代嘧啶嘧啶，治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有四取代嘧啶嘧啶的组合物与一种或多种附加制剂的组合物。
• Methods, compositions, and kits for the treatment of ophthalmic disorders
  申请人：CombinatoRx, Inc.

  公开号：EP2218442A1

  公开（公告）日：2010-08-18

  The invention features methods, compositions and kits comprising a corticosteroid and a non-steroidal immunophilin-dependent immunosuppressant for treating an ophthalmic disorder in a patient, wherein at least one of said corticosteroid and said non-steroidal immunophilin-dependent immunosuppressant is present at a low concentration, in particular wherein said corticosteroid is prednisolone acetate and said non-steroidal immunophilin-dependent immunosuppressant is cyclosporine A.

  本发明的特征是包含皮质类固醇和非类固醇免疫嗜血素依赖性免疫抑制剂的方法、组合物和试剂盒，用于治疗患者的眼科疾病、其中，所述皮质类固醇和所述非类固醇免疫嗜血素依赖性免疫抑制剂中至少有一种以低浓度存在，特别是所述皮质类固醇为醋酸泼尼松龙，所述非类固醇免疫嗜血素依赖性免疫抑制剂为环孢素 A。
• Combination therapy for the treatment of immunoinflammatory disorders
  申请人：——

  公开号：US20040224876A1

  公开（公告）日：2004-11-11

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering a non-steroidal immunophilin-dependent immunosuppressant (NsIDI) and an NsIDI enhancer (NsIDIE) or analog or metabolite thereof to the patient. The invention also features a pharmaceutical composition containing an NsIDI and NsIDIE or analog or metabolite thereof for the treatment or prevention of an immunoinflammatory disorder.

  本发明的特点是通过向患者施用非甾体类免疫嗜血素依赖性免疫抑制剂（NsIDI）和NsIDI增强剂（NsIDIE）或其类似物或代谢物来治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明还具有一种含有 NsIDI 和 NsIDIE 或其类似物或代谢物的药物组合物，用于治疗或预防免疫炎症性疾病。
• Methods and reagents for the treatment of immunoinflammatory disorders
  申请人：Keith Curtis

  公开号：US20050119160A1

  公开（公告）日：2005-06-02

  The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination with one or more additional agents.

  本发明的特点是通过向患者单独或与一种或多种附加制剂联合使用四取代嘧啶嘧啶，治疗被诊断患有或有可能患上免疫炎症性疾病的患者。本发明的另一个特点是含有四取代嘧啶嘧啶的组合物与一种或多种附加制剂的组合物。